OncoMed Pharma (OMED) Reports In-Line Q3 EPS

OncoMed Pharma (NASDAQ: OMED) reported Q3 EPS of ($0.77), in-line with the analyst estimate of ($0.77). Revenue for the quarter came in at $5.9 million versus the consensus estimate of $9.48 million.

Cash, cash equivalents and short-term investments totaled $207.6 million as of September 30, 2016, compared to $171.5 million as of June 30, 2016. The company’s cash balance includes net proceeds of $59.2 million from a follow-on offering completed August 23, 2016.

For earnings history and earnings-related data on OncoMed Pharma (OMED) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• SanDisk upgraded at JPMorgan after investor day; shares climb